Fig. 3

Neuronal loss and glial activation in the hippocampus of Dox-administered hTau368 mice. a Representative immunofluorescent images of NeuN- and GFAP-labeled cells in the hippocampus of homozygous hTau368 mice following 2 months of Veh and Dox treatment. b–e Dox-treated homozygous hTau368 mice had decreased number of NeuN-labeled neurons in DG hilus, relatively lower NeuN immunoreactivity in the CA1 pyramidal layer (b, d), and decreased number of MAP2-labeled neurons in the DG hilus (c, e). Unpaired Student’s t-test, *P < 0.05, ***P < 0.001; n = 6 mice per group. f Representative morphology of GFAP-labeled astrocyte. g Schematic diagram of Sholl analysis. h–l Dox-administered homozygous hTau368 mice had increased number and morphological complexity of GFAP-labeled astrocytes in the hippocampus. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired Student’s t-test, n = 3–5 mice per group. For Sholl analysis, n = 10 astrocytes from 5 mice per group. m–q Dox-administered homozygous hTau368 mice had increased number and morphological complexity of Iba1-labeled microglia in the hippocampus. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired Student’s t-test, n = 3–5 mice per group. For Sholl analysis, n = 10 cells from 5 mice per group